Special Issue

Exploring Antiangiogenic Agents in Drug Discovery: Molecular Mechanisms and Therapeutic Implications

Message from the Guest Editor

Angiogenesis, the formation of new blood vessels from pre-existing ones. While it is essential for tissue repair, wound healing, and embryonic development, its dysregulation can contribute to various diseases such as cancer, cardiovascular diseases, and retinal disorders. It is also involved in the pathogenesis of inflammatory diseases such as rheumatoid arthritis, where it can foster the infiltration of inflammatory cells into the joints. Therefore, the inhibition of angiogenesis in disease pathways has become crucial for the development of new therapeutic strategies for diseases.

We invite authors to submit original research and review articles on phytochemicals or synthetic compounds that inhibit angiogenesis via their mechanistic pathways as potential antiangiogenic agents. Potential topics include, but are not limited to, the following:

- Mechanistic pathways involving growth factors in preclinical and clinical models;
- Crosstalk signaling as part of antiangiogenic mechanisms;
- Exploring synergistic approaches and leveraging computational tools to accelerate the development of more effective and targeted anti-angiogenic therapies;
- Recent advancements in antiangiogenic therapy.

Guest Editor

Dr. Roslida Abdul Hamid

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia

Deadline for manuscript submissions

31 January 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/244526

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).